Skip to main content
. 2022 Nov 29;13:969509. doi: 10.3389/fimmu.2022.969509

Table 2.

Clinicopathologic characteristics of the RA patients and HC donors from discovery cohort.

Discovery cohort RA (n = 96) HC (n = 90)
Age, (mean ± SD) 51 ± 15 39 ± 11
Sex, Female (%) 82 (85.4) 76 (84.4)
Disease duration years, (mean ± SD) 10.0 ± 8.7
SJC, (mean (range)) 4 (0-28)
TJC, (mean (range)) 6 (0-28)
ESR, (mm/hour, (mean ± SD)) 35.6 ± 27.2
CRP, (mg/L, (mean ± SD)) 21.2 ± 31.9
RF positive (%) 47 (49.0)
CCP positive (%) 48 (50.0)
DAS28 score, (mean ± SD) 4.2 ± 1.6
ANA positive (%) 15 (15.6)
Low C3 (%) 3 (3.1)
Low C4 (%) 7 (7.3)
IGA, (g/L, (mean ± SD)) 2.8 ± 1.2
IGG, (g/L, (mean ± SD)) 14.7 ± 5.1
IGM, (g/L, (mean ± SD)) 1.2 ± 0.6
Current drug use
Oral glucocorticoid treatment (%) 32 (33.3)
DMARD (%) 45 (46.9)
Oral anticoagulant (%) 2 (2.1)
Aspirin (%) 3 (3.1)
Biologics (%) 6 (6.3)
Tripterygium glycosides (%) 15 (15.6)

SD, standard deviation; SJC, swollen joint count; TJC, tender joint count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; CCP, anti-cyclic citrullinated peptide antibody; DAS28, disease activity score (28-joint count); ANA, anti-nuclear antibody; C3, complement 3; C4, complement 4; IGA, immunoglobulin A; IGG, immunoglobulin G; IGM, immunoglobulin M; DMARD, disease modifying antirheumatic drug.